






#ResearchAtRisk

Pancreatic cancer is the 5th biggest cancer killer, yet it has received less than 1% of cancer research funding in the last decade

1%



among all cancers



# Pancreatic Cancer UK

## Pancreatic Cancer UK 2017 General Election Manifesto

**Pancreatic cancer has the worst survival rate of the 20 most common cancers in the UK. Around 9,600 people in the UK are diagnosed with pancreatic cancer each year and one person dies from the disease every hour<sup>1</sup>.**

Just 5% of people with pancreatic cancer survive five years or more, compared to over 50% of cancer patients overall<sup>2</sup>. It is unacceptable that people with pancreatic cancer have to endure survival odds that other cancers left behind in the 1970s.

We need to radically increase survival for pancreatic cancer. Pancreatic cancer research funding needs to reach at least £25 million per year to achieve the kind of breakthroughs necessary to significantly improve outcomes<sup>3</sup>. The disease is the cause of 5% of cancer deaths in the UK<sup>4</sup>. Yet, it has received less than 1% of total UK cancer research funding over the last decade. In addition, the EU currently spends at least £6.2 million on pancreatic cancer research in the UK. With Britain set to exit the EU, we cannot afford to lose access to European funding, collaboration and clinical trials.

Currently only 8% of patients receive surgery, the only hope of a cure<sup>5</sup>. This is in part due to patients being diagnosed late when the cancer is already advanced<sup>6</sup>.

Pancreatic cancer patients face a persistent lack of access to new treatments. Currently the only National Institute for Health and Care Excellence (NICE) approved treatment for pancreatic cancer is gemcitabine, which was made available 16 years ago. No new pancreatic cancer drugs have been approved by NICE since then. The quality of care received by pancreatic cancer patients often falls short of expected standards.

For example, the 2015 National Cancer Patient Experience Survey for England found that only 75% of pancreatic cancer patients felt they were given their diagnosis sensitively, compared to 84% of all cancer patients<sup>7</sup>.

With pancreatic cancer set to become the fourth biggest cancer killer by 2026<sup>8</sup>, we desperately need the next government to commit to improving survival and care outcomes now. We call on parliamentarians to change the story for pancreatic cancer patients by:

1. **Guaranteeing EU funding for research and access to international clinical trials #ResearchAtRisk**
2. **Significantly increasing funding and infrastructure for pancreatic cancer research**
3. **Ensuring fair access to treatments for less survivable cancers**
4. **Investing in early diagnosis to secure better outcomes for pancreatic cancer patients**
5. **Improving the quality of care for pancreatic cancer patients from diagnosis through to end of life care**
6. **Committing to the successful delivery of the Cancer Strategy by 2020**

Help support our manifesto calls by sharing on Twitter and Facebook. Tweet [@PancreaticCanUK](https://twitter.com/PancreaticCanUK) and use [#ResearchAtRisk](https://twitter.com/ResearchAtRisk).

Find out more at [pancreaticcancer.org.uk/generalelectionmanifesto](http://pancreaticcancer.org.uk/generalelectionmanifesto)

# #ResearchAtRisk